Sparrow BioAcoustics Secures $13 Million in Seed Round for Groundbreaking Stethophone™ Technology

Sparrow BioAcoustics is thrilled to announce the successful closing of a $13 million funding round, a significant milestone that will propel the company's mission to revolutionize clinical diagnostics. At the forefront of this transformation is the Stethophone™, the only FDA-cleared smartphone stethoscope available in the market today. This groundbreaking device leverages existing technology, allowing healthcare providers to turn their smartphones into medical-grade stethoscopes without requiring additional equipment to carry, charge, or connect. With its superior audio quality and robust features, the Stethophone™ provides dynamic visualizations of recordings, advanced analytical capabilities, and secure examination transmission—ultimately enhancing the detection and diagnosis processes. The funding will be utilized to scale production, enhance software capabilities, and expand market reach to ensure that healthcare professionals around the globe can benefit from this innovative solution. By bridging the gap in medical technology, Sparrow BioAcoustics aims to increase access to critical diagnostic tools, thereby improving clinical outcomes and paving the way for better health management practices. As the healthcare landscape evolves, Sparrow is committed to ensuring that every clinician has access to the best tools available, all from the convenience of their smartphones. With this new investment, Sparrow BioAcoustics is poised to make a significant impact on the lives of patients and healthcare providers alike, ushering in a new era of accessible and efficient medical diagnostics.